SV Health Investors Acquires EpiVax Immunogenicity CRO

SV Health Investors has strategically acquired EpiVax, Inc., a prominent bioanalytical contract research organization (CRO) with over two decades of expertise in assessing immunogenicity risks for drug developers. This acquisition marks a significant platform investment for SV Health Investors, leveraging their extensive experience in the outsourced pharmaceutical services sector. The deal aims to bolster EpiVax's capabilities and accelerate its growth trajectory within the competitive life sciences industry.

EpiVax, based in Providence, Rhode Island, has established itself as a critical partner for pharmaceutical and biotechnology firms, offering specialized pre-clinical drug development services. Their proprietary computational tools, including the ISPRI platform, alongside in vitro laboratory services, are designed to identify potential safety and efficacy concerns early in the development process. This proactive approach helps clients reduce development timelines and mitigate costly R&D expenditures, a crucial advantage in a market where speed to market is paramount.

The integration of EpiVax into SV Health Investors' portfolio is expected to enhance the CRO's service offerings. Future plans include the introduction of advanced computational tools, expanded cell-based assay applications, and broader analytical consulting services. This expansion is designed to further solidify EpiVax's leadership in immunogenicity risk assessment and improve its capacity to support global partners in refining their regulatory strategies and resource management.

A.J. Rossi, Partner at SV Health Investors, highlighted the firm's excitement about supporting EpiVax's management team. "We are eager to provide strategic guidance, capital, and access to our robust life sciences ecosystem," stated Rossi. "Our goal is to foster continued growth while preserving the company’s distinct culture and unwavering commitment to its clients." This approach aligns with SV Health Investors' established model of collaborating with founders and management to cultivate leading healthcare businesses.

Dr. Richard-Henry Schabowsky, CEO of EpiVax, expressed optimism about the partnership. "This collaboration with SV Health Investors significantly strengthens our position as a leader in immunogenicity risk assessment," he commented. "It will accelerate our innovation and enhance our ability to help pharmaceutical and biotech partners navigate complex development pathways more efficiently." The company's deep scientific foundation, evidenced by over 230 peer-reviewed publications, provides a strong basis for future advancements.

SV Health Investors, with offices in Boston and London and managing over $2.0 billion in assets, brings a wealth of sector expertise in tech-enabled pharma services. Their investment history includes notable companies such as Adimab, Clario, Celerion, and Leiters, underscoring their strategic focus on high-growth areas within healthcare. The acquisition of EpiVax is poised to capitalize on the growing demand for specialized CRO services, a market segment that benefits from increasing complexity in drug development and stringent regulatory requirements.